Du är här

2016-02-19

Medical Prognosis Institute: MPI's spinout OV has in-licensed LiPlaCis(TM):

Hoersholm; February 19, 2016 - Medical Prognosis Institute A/S (MPI.CO)
(Denmark and Phoenix, AZ, USA) announced today that MPI's spinout OV has
in-licensed LiPlaCis.

Oncology Venture a spinout from MPI's has today announced in-licensing of
LiPlaCis(TM) from LiPlasome Pharma ApS, Denmark. LiPlaCis will be the first
prospective trial using the Drug Response Predictor - DRP(TM) from MPI.
LiPlaCis(TM) - a liposomal formulation of cisplatin - is just finalizing the
dose escalation part of a phase 1 study in solid tumors and is on the verge
of moving into the extension phase where screened breast cancer patients with
metastatic disease will be treated.
Using analysis of patients own biopsies by the DRP(TM) patients are screened
beforehand for high likelihood of effect of the LiPlaCis(TM) drug. The
DRP(TM) should thereby enable a high response rate and give breast cancer
patients a new effective treatment opportunity.

"This is a key step for MPI - the team in OV has the last three years worked
with MPI and LiPlasome on LiPlaCis(TM)",

Said Adjunct professor Peter Buhl Jensen, MD, PhD and CEO of MPI

. "The MPI and OV teams know the project well and we trust that LiPlaCis(TM)
can
by the use of the MPI DRP(TM) be developed into a new effective treatment
opportunity for breast cancer patients",

Dr. Buhl Jensen further commented

."

For further information, please contact
CEO Peter Buhl Jensen, Adjunct professor, MD, PhD
Telephone: +45 21 60 89 22
E-mail: pbj@medical-prognosis.com

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop
tumor-derived gene signatures that may predict which cancer patients are
highly likely responders to a given anticancer product. The DRP(TM) has been
tested in 37 trials, where 29 trials showed that drug-specific DRP(TM)
Biomarkers could predict which patients had a positive effect of the
treatment. The DRP(TM) platform has also been externally validated and
published in collaboration with leading statisticians at the MD Anderson
Cancer Center. The DRP(TM) method can be used to design the Clinical
Development Plan, i.e. to select which indications are relevant for a given
anticancer drug. Further to and in addition to this, individual patients'
gene patterns can be analyzed as part of a screening procedure for a clinical
trial to ensure inclusion of those patients who have a high likelihood of
response to the drug. This DRP(TM) method builds on the comparison of
sensitive and resistant human cancer cell lines including genomic information
from cell lines combined with clinical tumor biology and clinical correlates
in a systems biology network. MicroRNA is used on certain products whereas
the messenger RNA is more broadly useable and more validated. The DRP(TM)
platform can be used in all cancer types and has been patented for more than
60 anticancer drugs in the US.

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with
cancer drug developers to apply its DRP(TM) diagnostic platform to streamline
and de-risk clinical trials and drug development via biomarker optimization,
patient stratification, and development of companion diagnostics.

For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.d.
e-mail: pbj@medical-prognosis.com
Phone: +45 21 60 89 22

Certified Advisor:

Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup,
Denmark

MPI's spinout OV has in-licensed LiPlaCis(TM)
http://hugin.info/158657/R/1987773/729704.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Prognosis Institute via Globenewswire

HUG#1987773

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.